Literature DB >> 22167582

Pharmacodynamic evaluation of irinotecan therapy by FDG and FLT PET/CT imaging in a colorectal cancer xenograft model.

Sarah R Mudd1, Kimberley D Holich, Martin J Voorbach, Todd B Cole, David R Reuter, Paul Tapang, Gail Bukofzer, Arunava Chakravartty, Cherrie K Donawho, Joann P Palma, Gerard B Fox, Mark Day, Yanping Luo.   

Abstract

PURPOSE: Longitudinal changes of 3'-[(18) F]fluoro-3'-deoxythymidine (FLT) and 2-deoxy-2-[(18) F]fluoro-D-glucose (FDG) in response to irinotecan therapy in an animal model of colorectal cancer were compared. PROCEDURES: SCID/CB-17 mice with HCT116 tumors were treated with 50 mg/kg irinotecan by intraperitoneal injection weekly for 3 weeks. FLT and FDG-positron emission tomography (PET) were performed at baseline, the day after each treatment, and 5 days after the first treatment. Proliferation and apoptosis were evaluated by immunohistochemistry (IHC) after day 15 of imaging.
RESULTS: Irinotecan treatment resulted in a suppression of tumor growth. Tumor FLT uptake was decreased the day after each treatment but to a lesser extent 5 days after the first treatment. FDG uptake increased the day after each treatment with a continuous increase throughout the experiment. IHC analysis of phospho-H3 and Ki67 confirmed FLT-PET results, indicating a decrease in proliferation the day after the final irinotecan treatment. Increased apoptosis monitored by caspase-3 was observed after day 15 with irinotecan treatment.
CONCLUSIONS: FLT-PET may be a better method than FDG-PET for assessing treatment response to irinotecan. Changes in imaging occur before changes in tumor volume.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22167582     DOI: 10.1007/s11307-011-0529-8

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  34 in total

1.  A quantitative analysis of the kinetics of the G(2) DNA damage checkpoint system.

Authors:  B D Aguda
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

2.  Apoptosis and changes in glucose transport early after treatment of Morris hepatoma with gemcitabine.

Authors:  U Haberkorn; M E Bellemann; G Brix; H Kamencic; I Morr; U Traut; A Altmann; J Doll; J Blatter; R Kinscherf
Journal:  Eur J Nucl Med       Date:  2001-04

Review 3.  Using imaging biomarkers to accelerate drug development and clinical trials.

Authors:  Homer H Pien; Alan J Fischman; James H Thrall; A Gregory Sorensen
Journal:  Drug Discov Today       Date:  2005-02-15       Impact factor: 7.851

Review 4.  Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development.

Authors:  Gary J Kelloff; John M Hoffman; Bruce Johnson; Howard I Scher; Barry A Siegel; Edward Y Cheng; Bruce D Cheson; Joyce O'shaughnessy; Kathryn Z Guyton; David A Mankoff; Lalitha Shankar; Steven M Larson; Caroline C Sigman; Richard L Schilsky; Daniel C Sullivan
Journal:  Clin Cancer Res       Date:  2005-04-15       Impact factor: 12.531

5.  Regulation and functional contribution of thymidine kinase 1 in repair of DNA damage.

Authors:  Yen-Ling Chen; Staffan Eriksson; Zee-Fen Chang
Journal:  J Biol Chem       Date:  2010-06-16       Impact factor: 5.157

Review 6.  Next generation topoisomerase I inhibitors: Rationale and biomarker strategies.

Authors:  Beverly A Teicher
Journal:  Biochem Pharmacol       Date:  2007-10-22       Impact factor: 5.858

7.  Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901.

Authors:  Julius Leyton; Graham Smith; Mark Lees; Meg Perumal; Quang-de Nguyen; Franklin I Aigbirhio; Oksana Golovko; Quimin He; Paul Workman; Eric O Aboagye
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

8.  Knockdown of the DNA repair and redox signaling protein Ape1/Ref-1 blocks ovarian cancer cell and tumor growth.

Authors:  Melissa L Fishel; Ying He; April M Reed; Helen Chin-Sinex; Gary D Hutchins; Marc S Mendonca; Mark R Kelley
Journal:  DNA Repair (Amst)       Date:  2007-10-31

9.  Early changes in [18F]FLT uptake after chemotherapy: an experimental study.

Authors:  Helmut Dittmann; Bernhard Matthias Dohmen; Rainer Kehlbach; Gabi Bartusek; Maren Pritzkow; Mario Sarbia; Roland Bares
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-09-06       Impact factor: 9.236

10.  Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3'-[(18)F]fluoro-3'-deoxythymidine ([(18)F]FLT) in pancreatic cancer cell lines.

Authors:  Ulrike Seitz; Martin Wagner; Bernd Neumaier; Edgar Wawra; Gerhard Glatting; Gerhard Leder; Roland M Schmid; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-06-04       Impact factor: 9.236

View more
  12 in total

1.  Diagnostic performance of ¹⁸F-fluorothymidine PET/CT for primary colorectal cancer and its lymph node metastasis: comparison with ¹⁸F-fluorodeoxyglucose PET/CT.

Authors:  Masatoyo Nakajo; Masayuki Nakajo; Yoriko Kajiya; Megumi Jinguji; Nobuaki Nishimata; Shunji Shimaoka; Tohru Nihara; Kuniaki Aridome; Sadao Tanaka; Yoshihiko Fukukura; Atushi Tani; Chihaya Koriyama
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-08       Impact factor: 9.236

2.  Evaluation of [18F]Fluorothymidine as a Biomarker for Early Therapy Response in a Mouse Model of Colorectal Cancer.

Authors:  Sara Rapic; Christel Vangestel; Jeroen Verhaeghe; David Thomae; Patrick Pauwels; Tim Van den Wyngaert; Steven Staelens; Sigrid Stroobants
Journal:  Mol Imaging Biol       Date:  2017-02       Impact factor: 3.488

3.  Combined Injection of (18)F-Fluorodeoxyglucose and 3'-Deoxy-3'-[(18)F]fluorothymidine PET Achieves More Complete Identification of Viable Lung Cancer Cells in Mice and Patients than Individual Radiopharmaceutical: A Proof-of-Concept Study.

Authors:  Xiao-Feng Li; Tao Huang; Huijie Jiang; Xuemei Wang; Baozhong Shen; Xiangcheng Wang; Chin K Ng; Gregory C Postel; A Cahid Civelek
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

4.  HIV infection accelerates gastrointestinal tumor outgrowth in NSG-HuPBL mice.

Authors:  Rong Lu; Shaoping Wu; Yongguo Zhang; Yinglin Xia; Erica J Huelsmann; Andrew T Lacek; Arman Nabatiyan; Maureen H Richards; Srinivas D Narasipura; Victoria Lutgen; Honglei Chen; Howard L Kaufman; Di Chen; Lena Al-Harthi; Andrew Zloza; Jun Sun
Journal:  AIDS Res Hum Retroviruses       Date:  2014-04-03       Impact factor: 2.205

Review 5.  Monitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studies.

Authors:  Mette Munk Jensen; Andreas Kjaer
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-10-12

6.  Imaging of treatment response to the combination of carboplatin and paclitaxel in human ovarian cancer xenograft tumors in mice using FDG and FLT PET.

Authors:  Mette Munk Jensen; Kamille Dumong Erichsen; Fredrik Björkling; Jacob Madsen; Peter Buhl Jensen; Maxwell Sehested; Liselotte Højgaard; Andreas Kjær
Journal:  PLoS One       Date:  2013-12-26       Impact factor: 3.240

7.  Longitudinal tumor hypoxia imaging with [(18)F]FAZA-PET provides early prediction of nanoliposomal irinotecan (nal-IRI) treatment activity.

Authors:  Jinzi Zheng; Stephan G Klinz; Raquel De Souza; Jonathan Fitzgerald; David A Jaffray
Journal:  EJNMMI Res       Date:  2015-10-19       Impact factor: 3.138

Review 8.  Preclinical Applications of 3'-Deoxy-3'-[18F]Fluorothymidine in Oncology - A Systematic Review.

Authors:  Sonja Schelhaas; Kathrin Heinzmann; Vikram R Bollineni; Gerbrand M Kramer; Yan Liu; John C Waterton; Eric O Aboagye; Anthony F Shields; Dmitry Soloviev; Andreas H Jacobs
Journal:  Theranostics       Date:  2017-01-01       Impact factor: 11.556

9.  [18F]-FLT positron emission tomography can be used to image the response of sensitive tumors to PI3-kinase inhibition with the novel agent GDC-0941.

Authors:  Christopher Cawthorne; Natalie Burrows; Roben G Gieling; Christopher J Morrow; Duncan Forster; Jamil Gregory; Marc Radigois; Alison Smigova; Muhammad Babur; Kathryn Simpson; Cassandra Hodgkinson; Gavin Brown; Adam McMahon; Caroline Dive; Duncan Hiscock; Ian Wilson; Kaye J Williams
Journal:  Mol Cancer Ther       Date:  2013-02-20       Impact factor: 6.261

10.  18F-fluorothymidine (FLT)-PET and diffusion-weighted MRI for early response evaluation in patients with small cell lung cancer: a pilot study.

Authors:  Tine Nøhr Christensen; Seppo W Langer; Katrine Engholm Villumsen; Helle Hjorth Johannesen; Johan Löfgren; Sune Høgild Keller; Adam Espe Hansen; Andreas Kjaer; Barbara Malene Fischer
Journal:  Eur J Hybrid Imaging       Date:  2020-01-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.